Skip to main content
. Author manuscript; available in PMC: 2009 Jun 23.
Published in final edited form as: Osteoarthritis Cartilage. 2007 Oct 22;16(5):566–571. doi: 10.1016/j.joca.2007.09.008

Table 1.

Baseline Characteristics of Study Subjects for the Incidence Radiographic hip OA (RHOA) and the Progression RHOA study.

Incidence
Study		 Progression
Study
No RHOA
(n=169)* 		Incident RHOA
(n=167)* 		Stable RHOA
(n=173)* 		Progression of
RHOA
(n=168)*
Age (years)
(Mean ± SD)		 69.6 ± 3.7 70.8 ± 4.6 † 71.8 ± 5.5 72.2 ± 5.5
Weight (kg)
(Mean ± SD)		 67.5 ± 11.2 67.4 ± 12.3 67.2 ± 11.4 68.3 ± 12.5
Height (cm)
(Mean ± SD)		 159.4 ± 5.6 159.9 ± 6.1 157.7 ± 6.1 160.0 ± 6.6 ‡
Hip pain
(% Positive)		 58 (35%) 57 (35%) 64 (37%) 79 (47%)
Estrogen use
(% Positive)		 24 (14%) 24 (14%) 16 (9%) 26 (16%)
Vitamin D use
(% Positive)		 83 (51%) 75 (46%) 87 (51%) 82 (50%)
Femoral Neck
BMD (g/cm2)
(Mean ± SD)		 0.66 ± 0.10 0.67 ± 0.11 0.65 ± 0.11 0.70 ± 0.13
Baseline serum
COMP
(u/L)
(Mean ± SD)		 11.06 ± 3.32 10.55 ± 2.93 10.66 ± 3.21 11.17 ± 3.60
Visit 4 Serum
COMP
(u/L)
(Mean ± SD)		 10.78 ± 2.98 12.27 ± 3.73 11.60 ± 3.54 11.08 ± 3.58
Baseline serum
NTX
(nM BCE)
(Mean ± SD)		 20.29 ± 8.97 20.52 ± 7.98 20.68 ± 7.29 20.89 ± 7.24
Visit 4 Serum
COMP
(nM BCE)
(Mean ± SD)		 19.54 ± 5.66 20.95 ± 7.86 20.43 ± 7.62 20.34 ± 6.47
*

Number of subjects ( ) represents all subjects with baseline characteristics and covariates collected.

RHOA=radiographic hip osteoarthritis, BMD=bone mineral density

†

p<0.05 versus subjects without RHOA

‡

p<0.005 versus subjects with stable RHOA